The European Commission has published a set of “fact sheets” in which it sets out what it sees as the benefits of its proposed reform of the EU pharmaceutical legislation, including the controversial plan to reduce the default period of regulatory data protection (RDP) on new drugs.
The four fact sheets, which also discuss plans to guide drug development towards unmet needs and to tackle drug shortages...